Loading
Pay a fixed prize, of tens of millions, to the first team to show that a completely new way of attacking cancer works in patients, so that the riskiest early bets are rewarded even before a product exists.
A prize schedule for pre-specified target classes or mechanisms with no approved analogue (for example a direct MYC inhibitor, a mutant p53 reactivator with objective responses, a therapy for dormant disseminated cells, a therapy that reverses cachexia) awarded at demonstrated human proof of concept: confirmed objective responses or biomarker-validated target engagement in a phase 1/2 trial with pre-registered criteria. The prize is paid regardless of commercial path, so academic and non-profit developers qualify. It complements, rather than replaces, market rewards, which arrive too late and too uncertainly for truly novel biology.
Shares The undruggable drivers, Incentives reward me-too drugs and marginal gains, TP53, KRAS.
Shares A billion-dollar prize for the first durable cure of a lethal metastatic cancer, Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape, Incentives reward me-too drugs and marginal gains.
Shares p53 / RB / cell-cycle checkpoint, The undruggable drivers, TP53.
Shares p53 / RB / cell-cycle checkpoint, The undruggable drivers, TP53.
Shares p53 / RB / cell-cycle checkpoint, RAS / RAF / MEK / ERK (MAPK), TP53, KRAS.
Shares Government reinsurance for phase 2 failures of first-in-class cancer drugs, Incentives reward me-too drugs and marginal gains.
Shares p53 / RB / cell-cycle checkpoint, TP53.
Shares The undruggable drivers, RAS / RAF / MEK / ERK (MAPK), KRAS.